Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada.
Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
Biomolecules. 2022 Oct 28;12(11):1590. doi: 10.3390/biom12111590.
There is an urgent need for exploring new actionable targets other than androgen receptor to improve outcome from lethal castration-resistant prostate cancer. Tumor metabolism has reemerged as a hallmark of cancer that drives and supports oncogenesis. In this regard, it is important to understand the relationship between distinctive metabolic features, androgen receptor signaling, genetic drivers in prostate cancer, and the tumor microenvironment (symbiotic and competitive metabolic interactions) to identify metabolic vulnerabilities. We explore the links between metabolism and gene regulation, and thus the unique metabolic signatures that define the malignant phenotypes at given stages of prostate tumor progression. We also provide an overview of current metabolism-based pharmacological strategies to be developed or repurposed for metabolism-based therapeutics for castration-resistant prostate cancer.
迫切需要探索除雄激素受体以外的新的可操作靶点，以改善致命性去势抵抗性前列腺癌的预后。肿瘤代谢已重新成为癌症的一个标志，它推动并支持肿瘤发生。在这方面，了解独特的代谢特征、雄激素受体信号、前列腺癌中的遗传驱动因素以及肿瘤微环境（共生和竞争代谢相互作用）之间的关系，以确定代谢弱点非常重要。我们探讨了代谢与基因调控之间的联系，从而确定了在前列腺肿瘤进展的特定阶段定义恶性表型的独特代谢特征。我们还概述了目前基于代谢的药理学策略，以开发或重新用于基于代谢的治疗去势抵抗性前列腺癌的方法。
